The Patent Ledger — Post 2: The Bayh-Dole Act

The Patent Ledger — FSA Intellectual Property Architecture Series · Post 2 of 6

Previous: Post 1 — The Bargain

What follows has never appeared in any intellectual property curriculum, innovation policy analysis, or pharmaceutical industry history.

The world was reading an incentive to innovate. FSA is reading the architecture that converted that incentive into the most sophisticated legal barrier to entry in the history of commerce.

BEFORE BAYH-DOLE — WHAT THE PUBLIC OWNED

From the 1940s through 1980 the federal government funded the majority of basic research in the United States — through the National Institutes of Health, the National Science Foundation, the Department of Defense, and the Department of Energy. This funding produced an extraordinary body of scientific knowledge: the foundations of the internet, the development of many cancer treatments, the mapping of molecular biology, the early work on what would become GPS.

When that federally funded research produced a patentable invention the default rule was clear: the federal government owned the patent. The public had paid for the research. The public owned the results. Any company could license the technology — on non-exclusive terms — and develop it into products. The knowledge entered the market as a public resource available to all competitors simultaneously.

By 1980 the federal government held approximately 28,000 patents from federally funded research. Fewer than 5% had been licensed to private companies. The argument made by Senators Birch Bayh and Bob Dole — and by the universities and pharmaceutical industry that lobbied for their bill — was that this low licensing rate represented wasted innovation. The inventions sat unused because no company would invest in developing them without the certainty of exclusive rights.

The argument was not unreasonable. The solution it produced was.

Before Bayh-Dole: the public funded the research and owned the results.

After Bayh-Dole: the public funded the research, the university patented it, the pharmaceutical company licensed it exclusively — and the public paid again at monopoly price. The Christmas Eve installation of intellectual property architecture.

WHAT BAYH-DOLE ACTUALLY DID — THE STRUCTURAL CHANGES

FSA — The Bayh-Dole Act · Structural Analysis · 1980

The Core Transfer

Bayh-Dole allowed universities, small businesses, and non-profits receiving federal research funding to retain ownership of patents on inventions arising from that research — and to grant exclusive licenses to private companies. For the first time a university could take federally funded research, patent the result, license it exclusively to a single pharmaceutical company, and collect royalties on products developed from public investment. The public research investment was converted into private monopoly rights.

The March-In Rights — The Protection That Doesn't Protect

Bayh-Dole included a safeguard: the federal government retained "march-in rights" — the authority to require the patent holder to license the technology to additional companies if the patent holder failed to develop the invention or if the public health required it. In 44 years since Bayh-Dole's passage the federal government has exercised march-in rights exactly zero times. Every petition to exercise march-in rights — including multiple petitions citing unaffordable drug prices on federally funded inventions — has been denied. The safeguard was installed and never activated. The insulation layer functions as designed.

The University Technology Transfer Industry

Bayh-Dole created an entirely new institutional function: the university technology transfer office. By 2024 virtually every research university in the United States operates a technology transfer office whose primary function is identifying patentable inventions in federally funded research, filing patent applications, and negotiating exclusive licensing deals with pharmaceutical and technology companies. US universities generate approximately $3 billion annually in licensing revenue. The university has become a patent licensing institution that also conducts teaching.

FSA Reading

Bayh-Dole is the Edict of Milan of intellectual property law. A transaction in which the public institution — Congress — transferred a sovereign right — ownership of publicly funded research — to private entities in exchange for the promise of more efficient commercialization. The promise was partially kept: more federally funded research was commercialized after 1980. The price was paid by the same public that funded the research — now required to purchase access to its own investment at monopoly prices set by the exclusive licensee. The public paid for the research. The public paid for the product. The entity in the middle collected both payments.

THE DRUG THAT PROVES THE CASE

FSA — Bayh-Dole In Practice · The Public Pays Twice Architecture

Xtandi (enzalutamide) — prostate cancer treatment. Developed at UCLA with NIH funding. Patent licensed exclusively to Astellas Pharma and Pfizer. US price: approximately $189,000 per year per patient. The same drug is sold in Canada for approximately $22,000 per year. The NIH — whose funding produced the drug — denied march-in rights petitions in 2023 citing Bayh-Dole's commercialization framework. The public paid for the research. The public pays $189,000 per year for the result. The march-in rights that could require affordable licensing have never been used in 44 years.

Taxol (paclitaxel) — cancer treatment. Discovered in a plant extract by USDA researchers. Developed into a drug by the NIH in partnership with Bristol-Myers Squibb under a Cooperative Research and Development Agreement. BMS received exclusive marketing rights. US pricing at launch: significantly higher than production cost. After patent expiration and generic entry the price dropped 99%. The monopoly price was not the price of development. It was the price of exclusivity.

The Bayh-Dole architecture is the indulgence economy running in pharmaceutical pricing. The fear is not purgatory — it is disease. The payment purchases access to the treatment rather than remission of sin. The treasury that controls access is the patent portfolio rather than the Treasury of Merit. The mechanism is identical. The institution that controls access extracts payment from those who need what only it can provide.

THE UNIVERSITY INCENTIVE PROBLEM — WHAT BAYH-DOLE DID TO SCIENCE

FSA maps the effect of Bayh-Dole on the research environment that produced the inventions it was designed to commercialize.

FSA — Bayh-Dole's Effect On Research Culture

Publication Delay

Before filing a patent application universities routinely delay or suppress publication of research results — because publication before patent filing destroys patentability in most jurisdictions. The open science norm — immediate publication of research results to advance the collective knowledge base — has been systematically subordinated to the patent filing timeline. The bargain that Bayh-Dole was designed to accelerate is slowed by the patent process that delivers its commercial benefit.

Research Direction Distortion

University technology transfer offices now play a role in evaluating research proposals — assessing commercial potential alongside scientific merit. Faculty researchers with commercially valuable patents generate licensing revenue for their institutions — creating institutional incentives that favor applied research with commercial applications over basic research whose value is collective and long-term. The research portfolio of American universities has shifted measurably toward patentable applications since 1980.

FSA Reading

Bayh-Dole solved a real problem — unused government patents sitting unlicensed — by creating a larger problem: converting the university from a public knowledge generator into a private IP licensing institution. The solution captured the institution it was supposed to serve. The Eternal Ledger principle: the counter-mechanism absorbed by the architecture it sought to constrain. Bayh-Dole was supposed to get public research into commercial use. It got public research into private portfolios instead.

⚡ FSA Live Node — The Biden March-In Rights Rule · 2024

In December 2023 the Biden administration issued a proposed rule clarifying that the federal government's Bayh-Dole march-in rights could be exercised when a drug developed from federally funded research was priced unaffordably — even if the drug was being commercialized. The pharmaceutical industry immediately challenged the rule — arguing it contradicted Bayh-Dole's intent and would chill investment in drug development from university patents.

The Biden administration finalized a framework for march-in rights in February 2024. The Trump administration — which took office in January 2025 — has not pursued march-in rights enforcement. In 44 years since Bayh-Dole the march-in rights have never been exercised. The counter-mechanism exists in the statute. It has never run.

1980: Bayh-Dole passes. March-in rights included as public safeguard. 2026: March-in rights exercised zero times. The safeguard that has never been used in 46 years is the insulation layer that makes the architecture politically defensible. The Jubilee proposed. The Jubilee not arriving.

THE FRAME CALLBACK

Post 1: The patent bargain gave inventors a temporary monopoly in exchange for permanent public knowledge. What arrived instead was an architecture designed to make the monopoly permanent — and the public knowledge transfer optional.

Post 2 adds the Bayh-Dole principle:

Post 2 — The Bayh-Dole Act

The public funded the research. The university patented it. The company licensed it exclusively.

The public paid again — at monopoly price — for access to its own investment. The march-in rights that could have prevented this have never been used. The Jubilee is in the statute. It does not arrive.

Next — Post 3 of 6

The Pharmaceutical Extension. How the drug industry converted the 20-year patent into a 40-year monopoly through systematic layering of secondary patents — new formulations, new dosages, new delivery mechanisms, new combinations — on top of expiring primary patents. Evergreening. The architecture that keeps a $10 generic drug selling for $300. Not by extending the original patent. By building a wall of secondary patents around it that makes generic entry legally impossible.

```

FSA Certified Node

Primary sources: Bayh-Dole Act — Patent and Trademark Law Amendments Act (1980) — public record. NIH march-in rights petition denials — NIH.gov, public record. Biden administration march-in rights framework (February 2024) — Federal Register, public record. AUTM university licensing statistics 2024 — public record. Xtandi pricing data: GoodRx, public record. NIH Research Portfolio data — public record. Mowery, D. et al., Ivory Tower and Industrial Innovation (2004). All sources public record.

Human-AI Collaboration

This post was developed through an explicit human-AI collaborative process as part of the Forensic System Architecture (FSA) methodology.

Randy Gipe · Claude / Anthropic · 2026

Trium Publishing House Limited · The Patent Ledger Series · Post 2 of 6 · thegipster.blogspot.com